Toxicology – Neuroleptic Malignant Syndrome (NMS) and Serotonin Syndrome (SS)

Definition

Neuroleptic malignant syndrome (NMS) and serotonin syndrome (SS) are potentially life-threatening hyperthermic syndromes associated with medications.

Both can cause:

• Altered mental status
• Hyperthermia
• Autonomic instability
• Abnormal muscle activity
• Rhabdomyolysis in severe cases

The major distinction is:

• NMS → dopamine blockade or withdrawal of dopaminergic therapy
• SS → excessive serotonergic activity

Their neuromuscular findings and speed of onset are particularly useful for distinguishing them.

Neuroleptic Malignant Syndrome (NMS)

NMS is primarily associated with reduced central dopaminergic activity.

Common Causes

NMS may occur after:

• Starting a dopamine antagonist
• Increasing the dose of an antipsychotic
• Using a potent dopamine-blocking medication
• Rapid dose escalation
• Abruptly stopping a dopaminergic medication

Important causative drugs include:

• Antipsychotics
• Metoclopramide
• Prochlorperazine
• Other dopamine receptor antagonists

NMS can also occur after abrupt withdrawal of drugs used to increase dopamine activity, such as levodopa.

Pathophysiology of NMS

Central dopamine receptor blockade, particularly involving D₂ receptors, interferes with:

• Hypothalamic thermoregulation
• Basal ganglia motor control
• Autonomic function

This can produce:

Dopamine blockade → severe rigidity + autonomic instability + hyperthermia + altered mental status

Severe muscle rigidity generates substantial heat and may cause extensive skeletal-muscle breakdown.

Clinical Features of NMS

The classic features are:

• Hyperthermia
• Altered mental status
• Severe generalized muscle rigidity
• Autonomic instability

Mental-status abnormalities include:

• Agitation
• Confusion
• Delirium
• Mutism
• Stupor
• Coma

Autonomic findings include:

• Tachycardia
• Hypertension
• Hypotension
• Diaphoresis
• Tachypnea
• Dysrhythmias

Muscular Findings in NMS

The characteristic finding is severe generalized “lead-pipe” rigidity.

Other extrapyramidal abnormalities may include:

• Tremor
• Bradykinesia
• Cogwheel rigidity
• Dystonia

The severe sustained muscle activity can produce:

• Elevated creatine kinase (CK)
• Rhabdomyolysis
• Hyperkalemia
• Acute kidney injury
• Hyperthermia

Laboratory Findings in NMS

Common abnormalities include:

• Markedly elevated CK
• Leukocytosis
• Elevated AST/ALT
• Metabolic acidosis
• Electrolyte abnormalities
• Myoglobinuria
• Acute kidney injury

CK elevation supports the diagnosis but is not specific for NMS.

The diagnosis remains primarily clinical.

Serotonin Syndrome

Serotonin syndrome results from excessive serotonergic activity in the CNS and peripheral nervous system.

It is usually associated with:

• Starting a serotonergic drug
• Increasing its dose
• Overdose
• Combining serotonergic medications
• Drug interactions that increase serotonin activity

Important Serotonergic Drugs

Potential causes include:

• SSRIs
• SNRIs
• MAO inhibitors
• Some tricyclic antidepressants
• Tramadol
• Dextromethorphan
• Linezolid
• Lithium
• Certain opioids with serotonergic activity
• Other serotonin-enhancing medications

The greatest risk often occurs when multiple serotonergic mechanisms are combined, especially combinations involving an MAO inhibitor.

Pathophysiology of Serotonin Syndrome

Excessive stimulation of serotonin receptors, particularly 5-HT₁A and 5-HT₂A receptors, produces the syndrome.

The characteristic clinical pattern consists of:

Mental-status changes + autonomic hyperactivity + neuromuscular hyperactivity

Mental-Status Findings in SS

Possible findings include:

• Anxiety
• Restlessness
• Agitation
• Confusion
• Delirium

Severe cases may produce:

• Seizures
• Coma

Autonomic Findings in SS

Common manifestations include:

• Diaphoresis
• Tachycardia
• Hypertension
• Hyperthermia
• Dilated pupils
• Increased bowel activity
• Diarrhea

Blood pressure can become unstable in severe cases.

Neuromuscular Findings in SS

The most important findings are:

• Clonus
• Hyperreflexia
• Tremor
• Myoclonus
• Increased muscle tone

Clonus may be:

• Spontaneous
• Inducible
• Ocular

Hyperreflexia and clonus are often particularly prominent in the lower extremities.

These findings are among the most useful clues distinguishing serotonin syndrome from NMS.

Hunter Serotonin Toxicity Criteria

Modern diagnosis commonly uses the Hunter Serotonin Toxicity Criteria rather than the older nonspecific criteria in the source.

In a patient with serotonergic exposure, serotonin toxicity is strongly supported by characteristic combinations involving:

• Spontaneous clonus
• Inducible clonus with agitation or diaphoresis
• Ocular clonus with agitation or diaphoresis
• Tremor with hyperreflexia
• Hypertonia with elevated temperature plus ocular or inducible clonus

The emphasis is therefore on clonus and hyperreflexia rather than nonspecific findings such as tachycardia alone.

Distinguishing NMS from Serotonin Syndrome

NMS

Think:

Dopamine blockade → slow onset → severe rigidity

Typical clues:

• Dopamine antagonist exposure
• Withdrawal of dopaminergic therapy
• Usually develops over days
• Severe generalized lead-pipe rigidity
• Bradykinesia
• Reflexes often normal or reduced
• Markedly elevated CK may occur
• GI hyperactivity is not characteristic

Serotonin Syndrome

Think:

Serotonin excess → rapid onset → clonus and hyperreflexia

Typical clues:

• Serotonergic medication exposure or interaction
• Usually develops within hours
• Hyperreflexia
• Clonus
• Tremor
• Myoclonus
• Diaphoresis
• Increased bowel sounds
• Diarrhea

High-Yield Distinction

NMS = rigidity + bradykinesia

SS = clonus + hyperreflexia

Onset

NMS

NMS generally develops more gradually.

Symptoms commonly evolve over approximately 1–3 days, although timing varies.

Serotonin Syndrome

Serotonin syndrome usually develops rapidly, often within hours of:

• Starting a serotonergic drug
• Increasing a dose
• Overdose
• Adding an interacting drug

Rapid onset strongly supports serotonin syndrome over NMS when the clinical findings are otherwise similar.

Hyperthermia

Both syndromes can cause dangerous hyperthermia.

The temperature elevation is largely generated by excessive skeletal-muscle activity, particularly in severe disease.

Complications include:

• Rhabdomyolysis
• Hyperkalemia
• Metabolic acidosis
• Acute kidney injury
• DIC
• Hepatic injury
• Cardiovascular collapse
• Multiorgan failure

Severe hyperthermia requires immediate treatment.

Differential Diagnosis

Other conditions that can resemble NMS or serotonin syndrome include:

• Malignant hyperthermia
• Sympathomimetic toxicity
• Anticholinergic syndrome
• MAOI toxicity
• Alcohol or sedative-hypnotic withdrawal
• Heat stroke
• Sepsis
• Meningitis/encephalitis
• Thyroid storm
• Severe agitation
• Status epilepticus
• Catatonia

The medication history and neuromuscular examination are especially important.

Malignant Hyperthermia

Malignant hyperthermia is usually triggered during anesthesia by:

• Certain volatile anesthetic agents
• Succinylcholine

Features include:

• Rapidly increasing CO₂ production
• Muscle rigidity
• Acidosis
• Hyperkalemia
• Rhabdomyolysis
• Hyperthermia

Dantrolene is the specific treatment for malignant hyperthermia.

It should not be confused with NMS merely because both conditions can involve rigidity and hyperthermia.

Sympathomimetic Toxicity

Stimulant poisoning can cause:

• Agitation
• Tachycardia
• Hypertension
• Mydriasis
• Diaphoresis
• Hyperthermia
• Tremor
• Seizures

However, the characteristic clonus and marked hyperreflexia of serotonin syndrome are generally absent.

Anticholinergic Syndrome

Anticholinergic toxicity can cause:

• Hyperthermia
• Agitated delirium
• Tachycardia
• Mydriasis

A useful clue is:

Anticholinergic → hot and dry

whereas serotonin syndrome commonly produces diaphoresis and increased bowel activity.

Diagnostic Evaluation

There is no single laboratory test that confirms either NMS or serotonin syndrome.

Evaluation should include:

• Detailed medication history
• Recent dose changes
• Drug interactions
• Neurologic examination
• Reflex examination
• Assessment for clonus
• Core temperature
• Hydration and perfusion status

Laboratory Tests

Important investigations in significant cases include:

• CK
• Electrolytes
• Glucose
• Renal function
• Liver enzymes
• CBC
• Blood gas when indicated
• Lactate
• Urinalysis
• ECG

Urinalysis may show evidence of myoglobinuria from rhabdomyolysis.

Other tests should be directed toward alternative diagnoses when necessary.

Management of Both Syndromes

Initial management includes:

• Stop the causative medication.
• Stabilize airway and breathing.
• Establish IV access.
• Begin cardiac monitoring.
• Monitor core temperature.
• Correct dehydration and electrolyte abnormalities.
• Control agitation.
• Treat seizures.
• Actively cool significant hyperthermia.

Severe cases require intensive monitoring.

Benzodiazepines

Benzodiazepines are particularly useful for:

• Agitation
• Tremor
• Seizures
• Excessive muscle activity

They can also decrease heat generation by reducing agitation and muscular activity.

They are especially important in serotonin syndrome.

Cooling

Hyperthermia should be treated with physical cooling, such as:

• Evaporative cooling
• Fans
• Other active external cooling measures

Antipyretics such as acetaminophen are generally ineffective because the temperature elevation is not caused by an increased hypothalamic set point.

Severe Hyperthermia

Extreme hyperthermia caused by sustained muscle activity may require:

• Deep sedation
• Endotracheal intubation
• Mechanical ventilation
• Neuromuscular paralysis

A nondepolarizing neuromuscular blocker is generally preferred when paralysis is required.

Rapid control of muscle activity is essential because continued rigidity can generate enormous amounts of heat.

Treatment of NMS

The most important intervention is:

Immediately stop the dopamine-blocking medication.

Supportive treatment includes:

• IV fluids when appropriate
• Cooling
• Correction of electrolyte abnormalities
• Treatment of rhabdomyolysis
• Management of renal complications
• Benzodiazepines

Most treatment is fundamentally supportive.

Dantrolene in NMS

Dantrolene reduces skeletal-muscle contraction and may be considered in selected severe NMS cases.

Evidence for its benefit in NMS is less established than for malignant hyperthermia.

It should therefore be regarded as an adjunct in selected severe cases, not a universal antidote for NMS.

Bromocriptine in NMS

Bromocriptine is a dopamine agonist that may be considered in selected moderate-to-severe NMS cases.

Other dopaminergic strategies may occasionally be used under specialist guidance.

Again, supportive care and removal of the offending drug remain central.

Treatment of Serotonin Syndrome

The first step is:

Stop all serotonergic medications.

Most mild-to-moderate cases improve with:

• Discontinuation of serotonergic drugs
• Benzodiazepines
• IV fluids when required
• Cooling
• Supportive care

Because many serotonergic drugs have relatively short effective durations, improvement can occur relatively quickly once the responsible agents are stopped.

Cyproheptadine

Cyproheptadine is a serotonin antagonist that may be considered in moderate or severe serotonin syndrome when supportive treatment and benzodiazepines are insufficient.

It is administered enterally rather than intravenously.

Evidence is largely based on clinical experience rather than high-quality randomized trials.

Blood Pressure Abnormalities

Both syndromes may produce:

• Hypertension
• Hypotension
• Rapid blood-pressure fluctuations

Hypertension often improves when:

• Agitation is controlled
• Rigidity decreases
• Hyperthermia is treated

Persistent severe abnormalities should be treated with short-acting, titratable agents appropriate to the patient’s hemodynamic state.

The source’s routine dopamine-first approach for hypotension is outdated; vasopressor choice should reflect the mechanism and current critical-care practice.

Rhabdomyolysis

Severe rigidity and hyperthermia can produce extensive skeletal-muscle breakdown.

Monitor:

• CK
• Potassium
• Creatinine
• Urine output
• Acid-base status

Complications include:

• Hyperkalemia
• Acute kidney injury
• Dysrhythmias

Decontamination

Do not induce vomiting.

Routine gastric lavage is not recommended.

Activated charcoal may be considered only after selected recent ingestions when:

• The drug is adsorbed by charcoal,
• Clinically significant toxicity is expected, and
• The airway can be safely protected.

Decontamination must never delay treatment of hyperthermia, seizures, rigidity, or cardiovascular instability.

Monitoring

Severe NMS or serotonin syndrome requires close monitoring of:

• Core temperature
• Mental status
• Cardiac rhythm
• Blood pressure
• Respiratory function
• CK
• Electrolytes
• Renal function
• Urine output

Patients with severe hyperthermia, rigidity, cardiovascular instability, seizures, or organ dysfunction generally require intensive-care management.

Expected Course

NMS

NMS generally:

• Develops more slowly
• Lasts longer
• May take days to resolve after the responsible drug is discontinued

Long-acting or depot antipsychotic exposure may prolong the syndrome.

Serotonin Syndrome

Serotonin syndrome generally:

• Begins rapidly
• Improves more rapidly after serotonergic drugs are stopped

Many uncomplicated cases improve substantially within about a day, although toxicity from long-acting agents or active metabolites can persist longer.

Key Points

• NMS and serotonin syndrome can both cause hyperthermia, altered mental status, autonomic instability, and abnormal muscle activity.
• NMS is associated with dopamine blockade or withdrawal of dopaminergic therapy.
• Serotonin syndrome results from excessive serotonergic activity.
• NMS generally has a slower onset with severe generalized rigidity and bradykinesia.
• Serotonin syndrome generally has a rapid onset with hyperreflexia and clonus.
• Clonus is one of the most useful findings suggesting serotonin syndrome.
• Diarrhea and increased bowel activity favor serotonin syndrome.
• Marked CK elevation and severe sustained rigidity are particularly characteristic of NMS, although they are not exclusive to it.
• The Hunter Serotonin Toxicity Criteria are commonly used to diagnose serotonin toxicity.
• Both syndromes can cause rhabdomyolysis, hyperkalemia, AKI, dysrhythmias, and multiorgan failure.
• Stop the causative medication immediately.
• Benzodiazepines, supportive care, and aggressive temperature control are central treatments.
• Cyproheptadine may be considered for significant serotonin syndrome.
• Dantrolene or bromocriptine may be considered in selected severe NMS cases.
• Antipyretics generally do not correct the hyperthermia because excessive muscle activity—not a raised hypothalamic set point—is the primary problem.
• Severe hyperthermia requires rapid control because prolonged extreme temperature can itself cause life-threatening organ injury.